This article is more than 5 years old. Information may no longer be current.

Sirion initiates enrollment for phase 2 study of geographic atrophy drug

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

TAMPA, Fla. — Sirion Therapeutics Inc. has begun enrolling patients in a phase 2 clinical trial of an oral compound for treating geographic atrophy in patients with age-related macular degeneration, the company announced.

Sirion acquired the fenretinide compound, called ST-602, in July through acquiring Systera Inc, a San Diego-based biopharmaceutical company. The randomized, double-masked, placebo-controlled, dose-comparison trial will evaluate the drug in 225 patients at approximately 20 sites in the U.S., according to a press release from Sirion.